Skip to main content
Top
Published in: Clinical and Translational Oncology 9/2020

01-09-2020 | Lung Cancer | Research Article

Impact of pre-radiation therapy quality of life in lung cancer survival: a prospective, intention-to-treat, multicenter study

Authors: J. M. Nieto-Guerrero Gómez, G. P. Silva Vega, J. Cacicedo, B. D. Delgado León, D. Herrero Rivera, J. M. Praena Fernández, E. Rivin del Campo, M. J. Ortiz Gordillo, J. L. López Guerra

Published in: Clinical and Translational Oncology | Issue 9/2020

Login to get access

Abstract

Purpose

Lung cancer (LC) has a significant impact on patients’ health-related quality of life (HRQoL). We investigate the correlations between pre-radiation therapy HRQoL and survival.

Materials and methods

A prospective, intention-to-treat, multicentre study of 437 patients with LC recruited at the radiation oncology departments of three different institutions was conducted between 2012 and 2016. QoL was assessed using the EORTC-QLQ-C30 (v3.0) and EORTC-QLQ-LC13 questionnaires. Global health status (GHS), physical (PF), role functioning (RF), emotional (EF), cognitive (CF), and social functioning (SF) as well as symptoms scores were evaluated in univariate and multivariate analyses.

Results

The cohort consisted of 376 men (86%) and 61 women, with a median age of 66 years (range 31–88). Histology was: 72% (n = 315) non-small cell lung cancer and 28% small cell lung cancer. The most common stage was III (80%) and the median follow-up for alive patients was 30 months (range 7–76). Multivariate analysis showed that RF was associated with a lower risk of mortality (HR: 0.693; p = 0.008) and recurrence (HR: 0.737; p = 0.040). Additionally, lower scores on EF and PF were associated with higher mortality (HR: 0.696; p = 0.003 and HR: 0.765; p = 0.044, respectively). Appetite loss, constipation, and dysphagia were associated with a higher risk of mortality (HR: 1.985; p < 0.001, HR: 1.373; p = 0.036, and HR: 1.659; p = 0.002, respectively), while appetite loss was the only symptom associated with a higher risk of recurrence (HR: 1.525; p = 0.014).

Conclusions

Pre-radiation therapy scores on RF, EF, and PF and symptoms like appetite loss, dysphagia, and constipation were associated with the risk of mortality. This information could be added to other prognostic factors to guide our treatment decisions.
Literature
1.
go back to reference Yin S, Njai R, Barker L, et al. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. Popul Health Metr. 2016;14:22.CrossRef Yin S, Njai R, Barker L, et al. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. Popul Health Metr. 2016;14:22.CrossRef
3.
go back to reference Reilly CM, Bruner DW, Mitchell SA, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013;21:1525–50.CrossRef Reilly CM, Bruner DW, Mitchell SA, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013;21:1525–50.CrossRef
4.
go back to reference Chen JE, Lou VW, Jian H, et al. Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients. Support Care Cancer. 2018;26:1265–72.CrossRef Chen JE, Lou VW, Jian H, et al. Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients. Support Care Cancer. 2018;26:1265–72.CrossRef
5.
go back to reference Petrosyan F, Daw H, Haddad A, Spiro T. Targeted therapy for lung cancer. Anticancer Drugs. 2012;23:1016–21.CrossRef Petrosyan F, Daw H, Haddad A, Spiro T. Targeted therapy for lung cancer. Anticancer Drugs. 2012;23:1016–21.CrossRef
6.
go back to reference Larsson M, Ljung L, Johansson BBK. Health-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data. Eur J Cancer Care. 2012;21:642–9.CrossRef Larsson M, Ljung L, Johansson BBK. Health-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data. Eur J Cancer Care. 2012;21:642–9.CrossRef
7.
go back to reference Lin SL, Chen YH, Yang L, Zhou JR. Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients. J Clin Nurs. 2013;22:1281–90.CrossRef Lin SL, Chen YH, Yang L, Zhou JR. Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients. J Clin Nurs. 2013;22:1281–90.CrossRef
8.
go back to reference Morrison EJ, Novotny PJ, Sloan JA, et al. Emotional problems, quality of life, and symptom burden in patients with lung cancer. Clin Lung Cancer. 2017;18:497–503.CrossRef Morrison EJ, Novotny PJ, Sloan JA, et al. Emotional problems, quality of life, and symptom burden in patients with lung cancer. Clin Lung Cancer. 2017;18:497–503.CrossRef
9.
go back to reference Dougall AL, Swanson J, Kyutoku Y, et al. Posttraumatic symptoms, quality of life, and survival among lung cancer patients. J Appl Biobehav Res. 2017;22:e12065.CrossRef Dougall AL, Swanson J, Kyutoku Y, et al. Posttraumatic symptoms, quality of life, and survival among lung cancer patients. J Appl Biobehav Res. 2017;22:e12065.CrossRef
10.
go back to reference Wang B, Hao N, Zhang X. Factors influencing the psychology and quality of life in lung cancer patients. Saudi Med J. 2017;38:948–51.CrossRef Wang B, Hao N, Zhang X. Factors influencing the psychology and quality of life in lung cancer patients. Saudi Med J. 2017;38:948–51.CrossRef
11.
go back to reference van der Linden N, Bongers ML, Coupe VMH, et al. Costs of non-small cell lung cancer in the Netherlands. Lung Cancer. 2016;91:79–88.CrossRef van der Linden N, Bongers ML, Coupe VMH, et al. Costs of non-small cell lung cancer in the Netherlands. Lung Cancer. 2016;91:79–88.CrossRef
12.
go back to reference Lefresne S, Olson R, Cashman R, et al. Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic. Lung Cancer. 2017;112:35–40.CrossRef Lefresne S, Olson R, Cashman R, et al. Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic. Lung Cancer. 2017;112:35–40.CrossRef
13.
go back to reference Ha D, Ries AL, Mazzone PJ, et al. Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancer. Support Care Cancer. 2018;26:2459–69.CrossRef Ha D, Ries AL, Mazzone PJ, et al. Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancer. Support Care Cancer. 2018;26:2459–69.CrossRef
14.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization-for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical-trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRef Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization-for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical-trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRef
15.
go back to reference Ran JT, Wang JB, Bi N, et al. Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. Radiat Oncol. 2017;12:195.CrossRef Ran JT, Wang JB, Bi N, et al. Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. Radiat Oncol. 2017;12:195.CrossRef
16.
go back to reference Hung HY, Wu LM, Chen KP. Determinants of quality of life in lung cancer patients. J Nurs Scholarsh. 2018;50:257–64.CrossRef Hung HY, Wu LM, Chen KP. Determinants of quality of life in lung cancer patients. J Nurs Scholarsh. 2018;50:257–64.CrossRef
17.
go back to reference Hechtner M, Krause M, Konig J, et al. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy—results of the randomized CHARTWEL trial. Radiother Oncol. 2018;126:283–90.CrossRef Hechtner M, Krause M, Konig J, et al. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy—results of the randomized CHARTWEL trial. Radiother Oncol. 2018;126:283–90.CrossRef
18.
go back to reference Choi S, Ryu E. Effects of symptom clusters and depression on the quality of life in patients with advanced lung cancer. Eur J Cancer Care. 2018;27:e12508.CrossRef Choi S, Ryu E. Effects of symptom clusters and depression on the quality of life in patients with advanced lung cancer. Eur J Cancer Care. 2018;27:e12508.CrossRef
19.
go back to reference Sarac S, Milic R, Vasiljevic M, Sarac M. Quality of life in patients with non-small cell lung cancer. Vojnosanit Pregl. 2017;74:625–32.CrossRef Sarac S, Milic R, Vasiljevic M, Sarac M. Quality of life in patients with non-small cell lung cancer. Vojnosanit Pregl. 2017;74:625–32.CrossRef
20.
go back to reference Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, Oñate-Ocaña LF, Zatarain-Barrón ZL, Barrón F, Arrieta O. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26:3029–38. https://doi.org/10.1007/s00520-018-4154-9 CrossRefPubMed Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, Oñate-Ocaña LF, Zatarain-Barrón ZL, Barrón F, Arrieta O. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26:3029–38. https://​doi.​org/​10.​1007/​s00520-018-4154-9 CrossRefPubMed
21.
go back to reference Xara S, Amaral TF, Parente B. Undernutrition and quality of life in non small cell lung cancer patients. Rev Port Pneumol. 2011;17:153–8.CrossRef Xara S, Amaral TF, Parente B. Undernutrition and quality of life in non small cell lung cancer patients. Rev Port Pneumol. 2011;17:153–8.CrossRef
22.
go back to reference Chasen M, Bhargava R, Hirschman S. Immunomodulatory agents for the treatment of cachexia. Curr Opin Support Palliat Care. 2014;8:328–33.CrossRef Chasen M, Bhargava R, Hirschman S. Immunomodulatory agents for the treatment of cachexia. Curr Opin Support Palliat Care. 2014;8:328–33.CrossRef
23.
go back to reference Grotmol KS, Lie HC, Hjermstad MJ, et al. W Depression-a major contributor to poor quality of life in patients with advanced cancer. J Pain Symptom Manag. 2017;54:889–97.CrossRef Grotmol KS, Lie HC, Hjermstad MJ, et al. W Depression-a major contributor to poor quality of life in patients with advanced cancer. J Pain Symptom Manag. 2017;54:889–97.CrossRef
24.
go back to reference Anatchkova MD, Bjorner JB. Health and role functioning: the use of focus groups in the development of an item bank. Qual Life Res. 2010;19:111–23.CrossRef Anatchkova MD, Bjorner JB. Health and role functioning: the use of focus groups in the development of an item bank. Qual Life Res. 2010;19:111–23.CrossRef
25.
go back to reference Li J, Bentzen SM, Li JL, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008;71:64–70.CrossRef Li J, Bentzen SM, Li JL, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008;71:64–70.CrossRef
Metadata
Title
Impact of pre-radiation therapy quality of life in lung cancer survival: a prospective, intention-to-treat, multicenter study
Authors
J. M. Nieto-Guerrero Gómez
G. P. Silva Vega
J. Cacicedo
B. D. Delgado León
D. Herrero Rivera
J. M. Praena Fernández
E. Rivin del Campo
M. J. Ortiz Gordillo
J. L. López Guerra
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02310-0

Other articles of this Issue 9/2020

Clinical and Translational Oncology 9/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine